Abstract
Introduction: High expression of secreted protein acidic and rich in cysteine (SPARC) has been associated with poorer overall survival (OS) in patients with resectable PC (Infante. J Clin Oncol. 2007). Among 36 patients with metastatic PC who received nab-P + Gem in a phase I/II study, a higher vs lower level of SPARC was associated with longer OS (median 17.8 vs 8.1 months; P = 0.043; Von Hoff. J Clin Oncol. 2011). The MPACT trial (N = 861), which revealed superior efficacy for nab-P + Gem vs Gem alone as first-line treatment for metastatic PC (OS, primary endpoint; median 8.5 vs 6.7 months; HR 0.72; P < 0.001; Von Hoff.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
